{"id":339477,"date":"2025-08-19T18:16:29","date_gmt":"2025-08-19T18:16:29","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-gilead-sciences\/"},"modified":"2025-08-19T18:16:29","modified_gmt":"2025-08-19T18:16:29","slug":"how-to-buy-gilead-sciences","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/","title":{"rendered":"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-339477","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Gilead Sciences, Inc. (GILD) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Gilead Sciences, Inc. (GILD) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin."},"intro":"HIV tedavisinde devrim yaratan bir ila\u00e7 devi olan Gilead Sciences (GILD)'e yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Gilead Sciences, t\u0131bbi yenilik ile finansal istikrar\u0131 birle\u015ftiriyor\u2014yeni yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. Biktarvy gibi \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler ve d\u00fcnyan\u0131n ilk y\u0131lda iki kez uygulanan HIV \u00f6nleme ilac\u0131yla, bu \u015firket d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131 etkiliyor. Mevcut hisse performans\u0131n\u0131, ak\u0131ll\u0131 giri\u015f stratejilerini ve 2025'in neden benzersiz f\u0131rsatlar sundu\u011funu birlikte ke\u015ffedece\u011fiz.","intro_source":{"label":"Intro","type":"text","formatted_value":"HIV tedavisinde devrim yaratan bir ila\u00e7 devi olan Gilead Sciences (GILD)'e yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Gilead Sciences, t\u0131bbi yenilik ile finansal istikrar\u0131 birle\u015ftiriyor\u2014yeni yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. Biktarvy gibi \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler ve d\u00fcnyan\u0131n ilk y\u0131lda iki kez uygulanan HIV \u00f6nleme ilac\u0131yla, bu \u015firket d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131 etkiliyor. Mevcut hisse performans\u0131n\u0131, ak\u0131ll\u0131 giri\u015f stratejilerini ve 2025'in neden benzersiz f\u0131rsatlar sundu\u011funu birlikte ke\u015ffedece\u011fiz."},"body_html":"<h2>\ud83d\udcc8 Gilead Sciences Hisse Senedi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>19 A\u011fustos 2025 itibar\u0131yla, Gilead Sciences, Inc. (GILD) NASDAQ'ta <strong>118,85 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014Gilead'\u0131n 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131\u011f\u0131 tarih. Tarihsel olarak, bu raporlar saatler i\u00e7inde \u00f6nemli fiyat hareketlerine neden olur.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 GILD Hissesini Nas\u0131l Hareket Ettirir<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>7 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>116,20 $<\/td><td><strong>%2,36 Art\u0131\u015f<\/strong> (mesai sonras\u0131)<\/td><\/tr> <tr><td>8 May 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>112,50 $<\/td><td><strong>%3,1 Art\u0131\u015f<\/strong> (ertesi g\u00fcn)<\/td><\/tr> <tr><td>6 \u015eub 2025<\/td><td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td><td>108,75 $<\/td><td><strong>%4,8 Art\u0131\u015f<\/strong> (tahminleri a\u015ft\u0131)<\/td><\/tr> <tr><td>7 Kas 2024<\/td><td>\u00dcr\u00fcn Lansman\u0131<\/td><td>104,30 $<\/td><td><strong>%2,9 Art\u0131\u015f<\/strong> (3 g\u00fcn)<\/td><\/tr> <tr><td>8 A\u011fu 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>102,10 $<\/td><td><strong>%1,2 D\u00fc\u015f\u00fc\u015f<\/strong> (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td><\/tr> <tr><td>9 May 2024<\/td><td>FDA Onay\u0131<\/td><td>98,40 $<\/td><td><strong>%5,3 Art\u0131\u015f<\/strong> (yat\u0131r\u0131mc\u0131 heyecan\u0131)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Analizi<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle fiyatlar\u0131 hemen y\u00fckseltirken, hedeflerin ka\u00e7\u0131r\u0131lmas\u0131 k\u0131sa vadeli d\u00fc\u015f\u00fc\u015flere neden olur\u2014ancak GILD, g\u00fc\u00e7l\u00fc HIV franchise hakimiyeti sayesinde genellikle h\u0131zl\u0131 toparlan\u0131r.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2> <p>Gilead hisseleri bu d\u00f6nemde etkileyici bir <strong>%28,2 b\u00fcy\u00fcme<\/strong> g\u00f6sterdi ve sekt\u00f6r\u00fcn %3,7 art\u0131\u015f\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde geride b\u0131rakt\u0131:<\/p> <ul> <li><strong>\u015eubat<\/strong>: 92,60 $ (tatil sonras\u0131 konsolidasyon)<\/li> <li><strong>Nisan<\/strong>: 105,80 $ (1. \u00e7eyrek kazan\u00e7lar\u0131 beklentileri a\u015ft\u0131)<\/li> <li><strong>Haziran<\/strong>: 112,40 $ (yeni tedaviler i\u00e7in FDA onay\u0131 heyecan\u0131)<\/li> <li><strong>A\u011fustos<\/strong>: 118,85 $ (2. \u00e7eyrek sonu\u00e7lar\u0131 tahminleri ge\u00e7ti)<\/li> <\/ul> <p><strong>Bu s\u00fcrekli y\u00fckseli\u015fin nedeni nedir?<\/strong><\/p> <ul> <li>HIV ila\u00e7 sat\u0131\u015flar\u0131 y\u0131ll\u0131k %7 art\u0131\u015fla 5,1 milyar $'a ula\u015ft\u0131<\/li> <li>Biktarvy, %49 ABD pazar pay\u0131n\u0131 koruyarak %9 sat\u0131\u015f b\u00fcy\u00fcmesi sa\u011flad\u0131<\/li> <li>FDA, y\u0131lda iki kez uygulanan devrim niteli\u011findeki HIV \u00f6nleme ilac\u0131 Yeztugo'yu onaylad\u0131<\/li> <li>\u015eirket, g\u00fc\u00e7l\u00fc performans nedeniyle tam y\u0131l rehberli\u011fini y\u00fckseltti<\/li> <\/ul>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 Y\u0131l Sonu<\/strong>: 125-135 $ (g\u00fc\u00e7l\u00fc tatil sat\u0131\u015flar\u0131 + pipeline kataliz\u00f6rleri) \u2192 <strong>AL<\/strong><br\/> <strong>2026<\/strong>: 140-150 $ (lenacapavir PrEP lansman\u0131 + pazar geni\u015flemesi)<br\/> <strong>2028<\/strong>: 160-180 $ (onkoloji portf\u00f6y\u00fc olgunla\u015fmas\u0131 + uluslararas\u0131 b\u00fcy\u00fcme)<br\/> <strong>2030<\/strong>: 200+ $ (ya\u015flanan n\u00fcfus talebi + \u00e7\u0131\u011f\u0131r a\u00e7an yenilikler)<\/p> <p><strong>Sonu\u00e7<\/strong>: <strong>Uzun vadeli tutu\u015flar<\/strong> i\u00e7in m\u00fckemmel. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar kazan\u00e7 sonras\u0131 f\u0131rsatlar\u0131 takip etmeli.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>GS-1720 ve GS-4182 HIV ila\u00e7lar\u0131nda FDA klinik durdurmalar\u0131<\/strong>\u201412-18 ayl\u0131k gecikmeler bekleniyor<\/li> <li><strong>\u00c7oklu pipeline programlar\u0131nda d\u00fczenleyici belirsizlik<\/strong><\/li> <li><strong>SEC soru\u015fturmalar\u0131 ve toplu davalar dahil yasal incelemeler<\/strong><\/li> <li><strong>Rekabet bask\u0131lar\u0131 nedeniyle H\u00fccre Tedavisi sat\u0131\u015flar\u0131nda %7 d\u00fc\u015f\u00fc\u015f<\/strong><\/li> <li><strong>\u00d6nemli uluslararas\u0131 gelir nedeniyle d\u00f6viz riski<\/strong><\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Yeztugo onay\u0131<\/strong> - y\u0131lda iki kez uygulanan d\u00fcnyan\u0131n ilk HIV \u00f6nleme ilac\u0131, 107 milyon $ debut \u00e7eyre\u011fi<\/li> <li><strong>Biktarvy hakimiyeti<\/strong> - %9 sat\u0131\u015f b\u00fcy\u00fcmesi ile 3,5 milyar $ ve %49 pazar pay\u0131<\/li> <li><strong>G\u00fc\u00e7l\u00fc finansallar<\/strong> - %21 net gelir art\u0131\u015f\u0131, 28,3-28,7 milyar $ rehberlik y\u00fckseltildi<\/li> <li><strong>6 milyar $ geri al\u0131m program\u0131<\/strong> y\u00f6netim g\u00fcvenini g\u00f6steriyor<\/li> <li><strong>Pipeline yenili\u011fi<\/strong> - lenacapavir denemelerde %100 etkinlik g\u00f6steriyor<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine d\u00fczenli yat\u0131r\u0131mla dolar maliyeti ortalamas\u0131 yap\u0131n<\/li> <li><strong>Kazan\u00e7 uyar\u0131lar\u0131 kurun<\/strong> - Potansiyel giri\u015f noktalar\u0131 i\u00e7in 5 Kas\u0131m civar\u0131nda GILD'i takip edin<\/li> <li><strong>Ak\u0131ll\u0131ca \u00e7e\u015fitlendirin<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %10-15'inden fazlas\u0131n\u0131 ila\u00e7 hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Esprili yakla\u015f\u0131m<\/strong>: \"GILD ticareti yapmak, HIV ila\u00e7lar\u0131n\u0131 almak gibidir\u2014tutarl\u0131l\u0131k zamanlamadan iyidir. Bir doz (veya dip) ka\u00e7\u0131r\u0131rsan\u0131z, sonra pi\u015fman olursunuz!\"<\/li> <\/ol>  <h2>\u2705 Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Yat\u0131r\u0131m platformu se\u00e7in<\/td><td>NASDAQ listeli hisseler ve par\u00e7al\u0131 hisse sunan bir platform oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Y\u00f6netilebilir miktarlarla ba\u015flay\u0131n\u2014par\u00e7al\u0131 yat\u0131r\u0131m i\u00e7in 50 $ bile yeterli<\/td><\/tr> <tr><td>3<\/td><td>\"GILD\" sembol\u00fcn\u00fc aray\u0131n<\/td><td>Sadece \"Gilead Sciences\" de\u011fil, tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n; volatilite s\u0131ras\u0131nda piyasa emirlerinden ka\u00e7\u0131n\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Komisyon \u00fccretlerini kontrol edin\u2014i\u015flem maliyetlerinin %0,5'in alt\u0131nda olmas\u0131na dikkat edin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Pocket Option, yeni ba\u015flayanlar i\u00e7in hisse senedi eri\u015fimini devrim niteli\u011finde kolayla\u015ft\u0131r\u0131r:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong>\u2014stratejileri risksiz test etmek i\u00e7in ideal<\/li> <li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong>\u2014herhangi bir kimlik belgesini y\u00fckleyin ve hemen ticarete ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto, e-c\u00fczdanlar, banka kartlar\u0131 ve yerel se\u00e7enekler<\/li> <li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong>\u2014k\u00fc\u00e7\u00fck sermayeyle bile GILD hisselerinin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <\/ul>  <h2>\ud83c\udf0d 2025'te Gilead Sciences: Sa\u011fl\u0131kta Yenilik Lideri<\/h2> <p>Gilead Sciences, Biktarvy ile ABD HIV tedavi pazar\u0131nda neredeyse %50 pazar pay\u0131na hakimdir. Antiviral ila\u00e7lar\u0131n \u00f6tesinde, \u015firket onkoloji ara\u015ft\u0131rmalar\u0131 ve inflamatuar hastal\u0131k tedavilerinde liderdir. <strong>2025 e\u011flenceli bilgi<\/strong>: Gilead'\u0131n Yeztugo onay\u0131, y\u0131lda sadece iki doz gerektiren ilk HIV \u00f6nleme se\u00e7ene\u011fini yaratarak d\u00fcnya \u00e7ap\u0131nda milyonlarca hayat\u0131 de\u011fi\u015ftirdi!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Gilead Sciences Hisse Senedi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>19 A\u011fustos 2025 itibar\u0131yla, Gilead Sciences, Inc. (GILD) NASDAQ&#8217;ta <strong>118,85 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014Gilead&#8217;\u0131n 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131\u011f\u0131 tarih. Tarihsel olarak, bu raporlar saatler i\u00e7inde \u00f6nemli fiyat hareketlerine neden olur.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 GILD Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>116,20 $<\/td>\n<td><strong>%2,36 Art\u0131\u015f<\/strong> (mesai sonras\u0131)<\/td>\n<\/tr>\n<tr>\n<td>8 May 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>112,50 $<\/td>\n<td><strong>%3,1 Art\u0131\u015f<\/strong> (ertesi g\u00fcn)<\/td>\n<\/tr>\n<tr>\n<td>6 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>108,75 $<\/td>\n<td><strong>%4,8 Art\u0131\u015f<\/strong> (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>7 Kas 2024<\/td>\n<td>\u00dcr\u00fcn Lansman\u0131<\/td>\n<td>104,30 $<\/td>\n<td><strong>%2,9 Art\u0131\u015f<\/strong> (3 g\u00fcn)<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>102,10 $<\/td>\n<td><strong>%1,2 D\u00fc\u015f\u00fc\u015f<\/strong> (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>FDA Onay\u0131<\/td>\n<td>98,40 $<\/td>\n<td><strong>%5,3 Art\u0131\u015f<\/strong> (yat\u0131r\u0131mc\u0131 heyecan\u0131)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Analizi<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle fiyatlar\u0131 hemen y\u00fckseltirken, hedeflerin ka\u00e7\u0131r\u0131lmas\u0131 k\u0131sa vadeli d\u00fc\u015f\u00fc\u015flere neden olur\u2014ancak GILD, g\u00fc\u00e7l\u00fc HIV franchise hakimiyeti sayesinde genellikle h\u0131zl\u0131 toparlan\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>Gilead hisseleri bu d\u00f6nemde etkileyici bir <strong>%28,2 b\u00fcy\u00fcme<\/strong> g\u00f6sterdi ve sekt\u00f6r\u00fcn %3,7 art\u0131\u015f\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde geride b\u0131rakt\u0131:<\/p>\n<ul>\n<li><strong>\u015eubat<\/strong>: 92,60 $ (tatil sonras\u0131 konsolidasyon)<\/li>\n<li><strong>Nisan<\/strong>: 105,80 $ (1. \u00e7eyrek kazan\u00e7lar\u0131 beklentileri a\u015ft\u0131)<\/li>\n<li><strong>Haziran<\/strong>: 112,40 $ (yeni tedaviler i\u00e7in FDA onay\u0131 heyecan\u0131)<\/li>\n<li><strong>A\u011fustos<\/strong>: 118,85 $ (2. \u00e7eyrek sonu\u00e7lar\u0131 tahminleri ge\u00e7ti)<\/li>\n<\/ul>\n<p><strong>Bu s\u00fcrekli y\u00fckseli\u015fin nedeni nedir?<\/strong><\/p>\n<ul>\n<li>HIV ila\u00e7 sat\u0131\u015flar\u0131 y\u0131ll\u0131k %7 art\u0131\u015fla 5,1 milyar $&#8217;a ula\u015ft\u0131<\/li>\n<li>Biktarvy, %49 ABD pazar pay\u0131n\u0131 koruyarak %9 sat\u0131\u015f b\u00fcy\u00fcmesi sa\u011flad\u0131<\/li>\n<li>FDA, y\u0131lda iki kez uygulanan devrim niteli\u011findeki HIV \u00f6nleme ilac\u0131 Yeztugo&#8217;yu onaylad\u0131<\/li>\n<li>\u015eirket, g\u00fc\u00e7l\u00fc performans nedeniyle tam y\u0131l rehberli\u011fini y\u00fckseltti<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 125-135 $ (g\u00fc\u00e7l\u00fc tatil sat\u0131\u015flar\u0131 + pipeline kataliz\u00f6rleri) \u2192 <strong>AL<\/strong><br \/> <strong>2026<\/strong>: 140-150 $ (lenacapavir PrEP lansman\u0131 + pazar geni\u015flemesi)<br \/> <strong>2028<\/strong>: 160-180 $ (onkoloji portf\u00f6y\u00fc olgunla\u015fmas\u0131 + uluslararas\u0131 b\u00fcy\u00fcme)<br \/> <strong>2030<\/strong>: 200+ $ (ya\u015flanan n\u00fcfus talebi + \u00e7\u0131\u011f\u0131r a\u00e7an yenilikler)<\/p>\n<p><strong>Sonu\u00e7<\/strong>: <strong>Uzun vadeli tutu\u015flar<\/strong> i\u00e7in m\u00fckemmel. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar kazan\u00e7 sonras\u0131 f\u0131rsatlar\u0131 takip etmeli.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>GS-1720 ve GS-4182 HIV ila\u00e7lar\u0131nda FDA klinik durdurmalar\u0131<\/strong>\u201412-18 ayl\u0131k gecikmeler bekleniyor<\/li>\n<li><strong>\u00c7oklu pipeline programlar\u0131nda d\u00fczenleyici belirsizlik<\/strong><\/li>\n<li><strong>SEC soru\u015fturmalar\u0131 ve toplu davalar dahil yasal incelemeler<\/strong><\/li>\n<li><strong>Rekabet bask\u0131lar\u0131 nedeniyle H\u00fccre Tedavisi sat\u0131\u015flar\u0131nda %7 d\u00fc\u015f\u00fc\u015f<\/strong><\/li>\n<li><strong>\u00d6nemli uluslararas\u0131 gelir nedeniyle d\u00f6viz riski<\/strong><\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Yeztugo onay\u0131<\/strong> &#8211; y\u0131lda iki kez uygulanan d\u00fcnyan\u0131n ilk HIV \u00f6nleme ilac\u0131, 107 milyon $ debut \u00e7eyre\u011fi<\/li>\n<li><strong>Biktarvy hakimiyeti<\/strong> &#8211; %9 sat\u0131\u015f b\u00fcy\u00fcmesi ile 3,5 milyar $ ve %49 pazar pay\u0131<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc finansallar<\/strong> &#8211; %21 net gelir art\u0131\u015f\u0131, 28,3-28,7 milyar $ rehberlik y\u00fckseltildi<\/li>\n<li><strong>6 milyar $ geri al\u0131m program\u0131<\/strong> y\u00f6netim g\u00fcvenini g\u00f6steriyor<\/li>\n<li><strong>Pipeline yenili\u011fi<\/strong> &#8211; lenacapavir denemelerde %100 etkinlik g\u00f6steriyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine d\u00fczenli yat\u0131r\u0131mla dolar maliyeti ortalamas\u0131 yap\u0131n<\/li>\n<li><strong>Kazan\u00e7 uyar\u0131lar\u0131 kurun<\/strong> &#8211; Potansiyel giri\u015f noktalar\u0131 i\u00e7in 5 Kas\u0131m civar\u0131nda GILD&#8217;i takip edin<\/li>\n<li><strong>Ak\u0131ll\u0131ca \u00e7e\u015fitlendirin<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %10-15&#8217;inden fazlas\u0131n\u0131 ila\u00e7 hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Esprili yakla\u015f\u0131m<\/strong>: &#8220;GILD ticareti yapmak, HIV ila\u00e7lar\u0131n\u0131 almak gibidir\u2014tutarl\u0131l\u0131k zamanlamadan iyidir. Bir doz (veya dip) ka\u00e7\u0131r\u0131rsan\u0131z, sonra pi\u015fman olursunuz!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Yat\u0131r\u0131m platformu se\u00e7in<\/td>\n<td>NASDAQ listeli hisseler ve par\u00e7al\u0131 hisse sunan bir platform oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Y\u00f6netilebilir miktarlarla ba\u015flay\u0131n\u2014par\u00e7al\u0131 yat\u0131r\u0131m i\u00e7in 50 $ bile yeterli<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;GILD&#8221; sembol\u00fcn\u00fc aray\u0131n<\/td>\n<td>Sadece &#8220;Gilead Sciences&#8221; de\u011fil, tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n; volatilite s\u0131ras\u0131nda piyasa emirlerinden ka\u00e7\u0131n\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretlerini kontrol edin\u2014i\u015flem maliyetlerinin %0,5&#8217;in alt\u0131nda olmas\u0131na dikkat edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Pocket Option, yeni ba\u015flayanlar i\u00e7in hisse senedi eri\u015fimini devrim niteli\u011finde kolayla\u015ft\u0131r\u0131r:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong>\u2014stratejileri risksiz test etmek i\u00e7in ideal<\/li>\n<li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong>\u2014herhangi bir kimlik belgesini y\u00fckleyin ve hemen ticarete ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto, e-c\u00fczdanlar, banka kartlar\u0131 ve yerel se\u00e7enekler<\/li>\n<li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong>\u2014k\u00fc\u00e7\u00fck sermayeyle bile GILD hisselerinin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Gilead Sciences: Sa\u011fl\u0131kta Yenilik Lideri<\/h2>\n<p>Gilead Sciences, Biktarvy ile ABD HIV tedavi pazar\u0131nda neredeyse %50 pazar pay\u0131na hakimdir. Antiviral ila\u00e7lar\u0131n \u00f6tesinde, \u015firket onkoloji ara\u015ft\u0131rmalar\u0131 ve inflamatuar hastal\u0131k tedavilerinde liderdir. <strong>2025 e\u011flenceli bilgi<\/strong>: Gilead&#8217;\u0131n Yeztugo onay\u0131, y\u0131lda sadece iki doz gerektiren ilk HIV \u00f6nleme se\u00e7ene\u011fini yaratarak d\u00fcnya \u00e7ap\u0131nda milyonlarca hayat\u0131 de\u011fi\u015ftirdi!<\/p>\n"},"faq":[{"question":"Gilead Sciences hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir yat\u0131r\u0131m platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"GILD\" sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak sipari\u015f verin ve i\u015flemi onaylay\u0131n."},{"question":"Gilead Sciences hisseleri i\u00e7in riskler nelerdir?","answer":"FDA klinik durdurmalar\u0131, d\u00fczenleyici belirsizlikler, yasal incelemeler, h\u00fccre tedavisi sat\u0131\u015flar\u0131ndaki d\u00fc\u015f\u00fc\u015f ve d\u00f6viz riski ba\u015fl\u0131ca risklerdir."},{"question":"2025 i\u00e7in Gilead Sciences hisse fiyat tahmini nedir?","answer":"2025 y\u0131l sonunda fiyat\u0131n 125-135 $ aras\u0131nda olmas\u0131 bekleniyor ve uzun vadede y\u00fckseli\u015f potansiyeli bulunuyor."},{"question":"Yeni ba\u015flayanlar i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"K\u00fc\u00e7\u00fck ba\u015flayarak d\u00fczenli yat\u0131r\u0131mlar yapmak, kazan\u00e7 uyar\u0131lar\u0131n\u0131 takip etmek ve portf\u00f6y\u00fc \u00e7e\u015fitlendirmek \u00f6nerilir."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve par\u00e7al\u0131 hisse al\u0131m imkan\u0131 sunar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Gilead Sciences hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir yat\u0131r\u0131m platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"GILD\" sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak sipari\u015f verin ve i\u015flemi onaylay\u0131n."},{"question":"Gilead Sciences hisseleri i\u00e7in riskler nelerdir?","answer":"FDA klinik durdurmalar\u0131, d\u00fczenleyici belirsizlikler, yasal incelemeler, h\u00fccre tedavisi sat\u0131\u015flar\u0131ndaki d\u00fc\u015f\u00fc\u015f ve d\u00f6viz riski ba\u015fl\u0131ca risklerdir."},{"question":"2025 i\u00e7in Gilead Sciences hisse fiyat tahmini nedir?","answer":"2025 y\u0131l sonunda fiyat\u0131n 125-135 $ aras\u0131nda olmas\u0131 bekleniyor ve uzun vadede y\u00fckseli\u015f potansiyeli bulunuyor."},{"question":"Yeni ba\u015flayanlar i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"K\u00fc\u00e7\u00fck ba\u015flayarak d\u00fczenli yat\u0131r\u0131mlar yapmak, kazan\u00e7 uyar\u0131lar\u0131n\u0131 takip etmek ve portf\u00f6y\u00fc \u00e7e\u015fitlendirmek \u00f6nerilir."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve par\u00e7al\u0131 hisse al\u0131m imkan\u0131 sunar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T18:16:29+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-19T18:16:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/\",\"name\":\"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-19T18:16:29+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/","og_locale":"tr_TR","og_type":"article","og_title":"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T18:16:29+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-19T18:16:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/","name":"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-19T18:16:29+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gilead-sciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences, Inc. (GILD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Gilead Sciences, Inc. (GILD) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":339478,"slug":"how-to-buy-gilead-sciences","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Gilead Sciences, Inc. (GILD) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Gilead Sciences, Inc. (GILD)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-gilead-sciences\/"},"pt_AA":{"locale":"pt_AA","id":339476,"slug":"how-to-buy-gilead-sciences","post_title":"Como comprar a\u00e7\u00f5es da Gilead Sciences, Inc. (GILD) - Investimento em a\u00e7\u00f5es da Gilead Sciences, Inc. (GILD)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-gilead-sciences\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/339477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=339477"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/339477\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=339477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=339477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=339477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}